|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 6/20/19 Acorda Therapeutics Inc 8-K:5 6/19/19 1:55K ActiveDisclosure/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 25K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 19, 2019
Acorda Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
|
13-3831168 |
|
|
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
|
of incorporation) |
|
File Number) |
|
Identification No.) |
|
|
|
|
|
|
|
|
|
420 Saw Mill River Road, |
|
|
|
|
|
(Address of principal executive offices) |
|
(Zip Code) |
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: (914) 347-4300 |
||||
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
|
|
|
Common Stock $0.001 par value |
|
ACOR |
|
Nasdaq Global Market |
|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Acorda Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 19, 2019 (the “Annual Meeting”). 45,128,571 shares of the Company’s common stock, or 93.82% of the shares of the Company’s common stock issued and outstanding on the record date for the Annual Meeting, were present in person or represented by proxy at the Annual Meeting. Summarized below are descriptions of the proposals voted on at the Annual Meeting and the final results of such voting:
Proposal One: Election of directors
As described in the Company’s 2019 Proxy Statement, the Company’s Board of Directors nominated three individuals to serve as Class II directors for a term to expire on the date of the Company’s 2022 Annual Meeting of Stockholders or until their successors are duly elected and qualified. All of such nominees were elected by a plurality vote (and also received a majority vote, for purposes of the majority vote provisions of the Company’s Bylaws), as follows:
|
Director |
Votes For |
Votes Withheld |
Broker Non-Votes |
|
Peder K. Jensen, M.D. |
39,516,867 |
2,776,495 |
2,835,209 |
|
John P. Kelley |
39,247,054 |
3,046,308 |
2,835,209 |
|
Sandra Panem, Ph.D. |
33,268,990 |
9,024,372 |
2,835,209 |
Proposal Two: Approval of the Acorda Therapeutics, Inc. 2019 Employee Stock Purchase Plan
The Company’s stockholders approved the Acorda Therapeutics, Inc. 2019 Employee Stock Purchase Plan by the following vote:
|
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|
42,215,837 |
65,048 |
12,477 |
2,835,209 |
Proposal Three: Ratification of appointment of independent auditors
The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent auditors for the fiscal year ending December 31, 2019, by the following vote:
|
Votes For |
Votes Against |
Abstentions |
|
44,963,523 |
159,090 |
5,958 |
Proposal Four: Advisory vote to approve named executive officer compensation
The Company’s stockholders voted, in an advisory, non-binding manner, to approve the compensation of the Company’s Named Executive Officers as disclosed in the Company’s 2019 Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, the executive compensation tables and the related footnotes and narrative accompanying the tables (the “say-on-pay vote”). The Company’s stockholders voted as follows to approve such executive compensation pursuant to the say-on-pay vote:
|
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|
37,961,055 |
637,577 |
3,694,730 |
2,835,209 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Acorda Therapeutics, Inc. |
|
|
|
|
|
|
By: |
/s/ David Lawrence |
|
|
|
|
Name: David Lawrence |
|
|
|
Title: Chief, Business Operations and Principal Accounting Officer |
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 12/31/19 | ||||
| Filed on: | 6/20/19 | |||
| For Period End: | 6/19/19 | DEF 14A | ||
| List all Filings | ||||